Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Stakeholders Ask FDA to Clarify Guidance on ‘Indications and Usage’ in Labeling

  • Post author:Sam
  • Post published:September 11, 2018
  • Post category:Drug Industry Daily

In comments on the FDA’s draft guidance on the Usage and Indication sections of drug labeling, Novartis and Pfizer asked the agency to clarify its thinking on limitations of use.…

Continue ReadingStakeholders Ask FDA to Clarify Guidance on ‘Indications and Usage’ in Labeling

FDA Proposes Removing New Drug Approval Step for Irradiated OTC Drugs

  • Post author:Sam
  • Post published:September 11, 2018
  • Post category:Drug Industry Daily

The FDA proposed a rule Tuesday to allow OTC drugs sterilized by irradiation to be marketed legally without an agency-approved NDA or ANDA. Source: Drug Industry Daily

Continue ReadingFDA Proposes Removing New Drug Approval Step for Irradiated OTC Drugs

FDA Slams Mexican Manufacturer for Numerous Violations

  • Post author:Sam
  • Post published:September 10, 2018
  • Post category:Drug Industry Daily

The FDA hit Guadalajara, Jalisco-based drug manufacturer Jabones y Productos Especializados (Soaps and Specialized Products) with a Form 483 for multiple violations, including serious quality deficiencies, observed during a March…

Continue ReadingFDA Slams Mexican Manufacturer for Numerous Violations

Florida Pharmacist Convicted of $5 Million Compounding Fraud

  • Post author:Sam
  • Post published:September 10, 2018
  • Post category:Drug Industry Daily

In the latest salvo in the federal crackdown on fraud among Florida compounders, a federal jury convicted pharmacist Stephen Chalker of participating in a $5 million scheme to defraud Medicare,…

Continue ReadingFlorida Pharmacist Convicted of $5 Million Compounding Fraud

Judge Dismisses Price-Fixing Suit Against Impax, Allows Amended Complaint

  • Post author:Sam
  • Post published:September 10, 2018
  • Post category:Drug Industry Daily

A California federal judge dismissed a shareholder suit against Impax Laboratories alleging price-fixing but left the door open for an amended complaint. Source: Drug Industry Daily

Continue ReadingJudge Dismisses Price-Fixing Suit Against Impax, Allows Amended Complaint

FDA Issues Guidance on Postapproval Manufacturing Changes for Synthetics

  • Post author:Sam
  • Post published:September 10, 2018
  • Post category:Drug Industry Daily

The FDA issued guidance Monday on how sponsors of synthetic drugs should approach post-approval manufacturing process changes — listing examples of low, medium and high risk changes. Source: Drug Industry…

Continue ReadingFDA Issues Guidance on Postapproval Manufacturing Changes for Synthetics

Gottlieb Announces Revised MOU on Interstate Distribution of Compounded Drugs

  • Post author:Sam
  • Post published:September 7, 2018
  • Post category:Drug Industry Daily

FDA Commissioner Scott Gottlieb announced a revised agreement Friday between the agency and states on interstate distribution of compounded drugs, responding to concerns that the existing distribution limits are too…

Continue ReadingGottlieb Announces Revised MOU on Interstate Distribution of Compounded Drugs

Juno to Settle Class-Action Suit Over Clinical Trial Deaths

  • Post author:Sam
  • Post published:September 7, 2018
  • Post category:Drug Industry Daily

More than a year after shutting down its CAR-T trial after subjects died, Juno Therapeutics agreed to pay $24 million to investors who claimed they were not properly informed. Source:…

Continue ReadingJuno to Settle Class-Action Suit Over Clinical Trial Deaths

Foundations Help Fund Nonprofit Generics Company

  • Post author:Sam
  • Post published:September 7, 2018
  • Post category:Drug Industry Daily

Three national foundations have committed $30 million to the launch of a not-for-profit generic drug company — first announced in January — citing the rising prices of generics and the…

Continue ReadingFoundations Help Fund Nonprofit Generics Company

Maryland AG Targets Insys for Alleged Subsys Fraud

  • Post author:Sam
  • Post published:September 7, 2018
  • Post category:Drug Industry Daily

Maryland’s Attorney General filed charges against Insys Therapeutics over alleged violations of the state’s Consumer Protection Act, saying the company joined local health care providers in an “unfair and deceptive…

Continue ReadingMaryland AG Targets Insys for Alleged Subsys Fraud
  • Go to the previous page
  • 1
  • …
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.